Shuttle Pharmaceuticals Holdings (SHPH) EBITDA (2021 - 2026)

Shuttle Pharmaceuticals Holdings has reported EBITDA for 6 years, with the latest figure at -$2.2 million in Q1 2026.

• On a quarterly basis, EBITDA rose 24.89% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 20.73% decrease from a year earlier, with the FY2025 full-year figure at -$11.9 million, down 54.84% from the prior year.
• EBITDA was -$2.2 million for Q1 2026 at Shuttle Pharmaceuticals Holdings, up from -$2.8 million in the prior quarter.
• The five-year high for EBITDA was -$353626.0 in Q2 2022, with the low at -$3.9 million in Q2 2025.
• Average EBITDA over 5 years is -$1.8 million, with a median of -$1.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA soared 46.35% in 2022, then tumbled 314.46% in 2023.
• Over 5 years, EBITDA stood at -$530336.0 in 2022, then slumped by 141.89% to -$1.3 million in 2023, then plunged by 38.53% to -$1.8 million in 2024, then slumped by 56.9% to -$2.8 million in 2025, then increased by 20.49% to -$2.2 million in 2026.
• The last three EBITDA figures came in at -$2.2 million (Q1 2026), -$2.8 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.